Nursing Care Plans Decreased Cardiac Output Nursing Diagnosis & Care Plan w/ Samples: Assessment & Interventions
When the heart can’t pump enough blood to meet the body’s needs, decompensation can show up quickly — tachycardia or dysrhythmia, cool clammy skin, delayed capillary refill, mental status changes, falling urine output, rising lactate, pulmonary congestion, and sometimes hypoxemia. Decreased cardiac output is one of the highest-priority cardiovascular nursing diagnoses you’ll write — and one of the most common NCLEX-RN® priority-judgment questions.
Let’s make this simple. This guide walks through the diagnosis the way it actually shows up on care plans — NANDA-I framing, assessment with rationales, SMART goals, interventions categorized by purpose, and five worked sample care plans (heart failure, acute MI, atrial fibrillation with RVR, cardiogenic shock, post-cardiac surgery) you can adapt for any patient.
Scope note: This care plan is for nursing education and does not replace facility protocols, provider orders, ACLS algorithms, or individualized clinical judgment. Escalate rapidly for hypotension, altered mental status, chest pain, acute heart failure, shock signs, falling urine output, or rising lactate.
In this guide
- What is decreased cardiac output?
- Pathophysiology
- Causes (Related to)
- Signs and symptoms (As evidenced by)
- Sample nursing diagnoses
- Goals and outcomes (SMART format)
- Nursing assessment with rationales
- Diagnostic tests
- Nursing interventions (with rationales)
- Sample care plans — 5 scenarios
- Escalation red flags (high-yield)
- Discharge and patient teaching
- Frequently asked questions
- Related care plans
- References
What is decreased cardiac output?
Decreased cardiac output is a NANDA-I nursing diagnosis describing inadequate blood pumped by the heart to meet the body’s metabolic demands.¹ Cardiac output (CO) is the volume of blood the heart pumps per minute, calculated as heart rate × stroke volume. Normal adult CO is roughly 4–8 L/min at rest, with cardiac index (CO/body surface area) of 2.5–4.0 L/min/m².²
Stroke volume itself depends on three things: preload (ventricular filling), afterload (resistance the heart pumps against), and contractility (how forcefully the heart squeezes). When any of these — or heart rate — is disrupted enough that the cascade outpaces compensation, you get decreased cardiac output.
For an anatomy and physiology refresher, see the StatPearls Physiology, Cardiac Output chapter.²
Don’t confuse these two cardiac diagnoses: Decreased cardiac output is about the pump itself — the heart can’t move enough blood. Ineffective tissue perfusion (peripheral, cerebral, renal, cardiopulmonary, or GI) is downstream — even with adequate output, blood may not reach specific tissues. A patient with decreased cardiac output may also meet criteria for an ineffective tissue perfusion diagnosis, but document it only when assessment data support impaired perfusion to a specific tissue or organ system.¹
Pathophysiology of decreased cardiac output
When cardiac output falls, the body activates compensatory mechanisms before symptoms appear:
- Sympathetic activation — increased heart rate and contractility, peripheral vasoconstriction. Maintains BP short-term but increases myocardial oxygen demand.
- Renin-angiotensin-aldosterone system (RAAS) — sodium and water retention to expand circulating volume. Helps preload short-term but causes congestion long-term (this is why diuretics and RAAS blockers are heart failure pillars).
- Frank-Starling reserve — ventricles stretch to accommodate more volume and pump more forcefully. Works until the ventricles overstretch, at which point contractility falls.
When compensation can’t keep up, decompensation follows: pulmonary congestion (left-sided failure → orthopnea, crackles, hypoxia), systemic congestion (right-sided failure → JVD, peripheral edema, hepatomegaly), and organ hypoperfusion (cool extremities, decreased urine output, altered mental status, rising lactate). Untreated, this progresses to cardiogenic shock.
For exams, focus on this: in early decreased cardiac output, the patient may have a normal BP because compensatory vasoconstriction is working. Look at trends in HR, capillary refill, urine output, and mental status — those decompensate before BP. By the time BP drops, the patient is already in trouble.
Causes (Related to)
On your care plan, the phrase after “Related to” should name the specific cause for your patient — not the broad category. NANDA-I groups the etiology of decreased cardiac output by which determinant of cardiac output is disrupted.¹
Altered heart rate or rhythm
- Bradycardia (sinus, complete heart block, sick sinus syndrome)
- Tachycardia (sinus, SVT, ventricular tachycardia)
- Atrial fibrillation, atrial flutter — especially with rapid ventricular response
- Heart blocks (1st, 2nd-degree Mobitz I/II, 3rd-degree)
- PVCs, ventricular tachycardia, ventricular fibrillation
Altered contractility
- Acute myocardial infarction or myocardial ischemia
- Heart failure with reduced ejection fraction (HFrEF)
- Cardiomyopathy (dilated, hypertrophic, restrictive)
- Myocarditis
- Post-cardiac-surgery myocardial stunning
- Negative-inotropic medications (beta-blockers, certain calcium-channel blockers, anesthetics)
Altered preload
- Hypovolemia, hemorrhage, severe dehydration
- Fluid overload in heart failure (excess preload can also reduce CO)
- Cardiac tamponade (Beck’s triad: hypotension, JVD, muffled heart sounds)
- Tension pneumothorax
- Massive pulmonary embolism
Altered afterload
- Severe hypertension
- Aortic stenosis
- Pulmonary hypertension
- Vasopressor effects (excessive vasoconstriction)
Structural and other
- Valvular disease (stenosis or regurgitation)
- Pericardial effusion, constrictive pericarditis
- Congenital heart disease
- Sepsis (combined distributive and cardiogenic features)
Signs and symptoms (As evidenced by)
A NANDA-I diagnostic statement is supported by defining characteristics. Use patient-reported (subjective) data when available, plus objective findings. For an alert patient, include both. For a sedated, unconscious, or critically ill patient, objective and hemodynamic findings alone are sufficient — inability to report does not negate the diagnosis.¹
Subjective data — what the patient reports
- Dyspnea on exertion or at rest
- Orthopnea (needs extra pillows to sleep), paroxysmal nocturnal dyspnea (PND)
- Fatigue, exercise intolerance
- Palpitations or irregular heartbeat sensation
- Chest pain, pressure, or discomfort
- Dizziness, lightheadedness, near-syncope or syncope
- Leg or abdominal swelling, weight gain
- Difficulty thinking clearly or concentrating
Objective data — what you observe
- Vital signs: tachycardia or bradycardia, hypotension (often a late sign), narrow pulse pressure, orthostatic changes
- Skin: cool, clammy, pale, cyanotic, diaphoretic; capillary refill > 3 seconds; mottling in shock
- Pulses: weak, thready, irregular; pulse deficit (apical–radial mismatch in AFib)
- Auscultation: S3 gallop (volume overload, classic HFrEF), S4 (stiff ventricle), new or worsening murmur, bibasilar crackles, rhonchi, wheezing
- JVP (jugular venous pressure) — measured vertically with the head of bed at 30–45°; JVP > 3–4 cm above the sternal angle indicates elevated right-sided pressures
- Edema: lower-extremity pitting edema (1+ to 4+), sacral edema in bedbound patients
- Mental status: restlessness, anxiety, new confusion — early sign of cerebral hypoperfusion
- Urine output: decreased (< 30 mL/hr in adults, or < 0.5 mL/kg/hr) — kidneys hypoperfused
- Activity intolerance: dyspnea or fatigue with previously tolerated activity
Measurable findings (labs, ECG, imaging)
- Reduced ejection fraction on echocardiogram (HFrEF if EF < 40%)
- ECG: dysrhythmia, ischemia (ST-segment changes), bundle branch block, axis deviation, ventricular hypertrophy
- BNP / NT-proBNP supports HF diagnosis and severity assessment when interpreted with clinical findings. BNP > 100 pg/mL can support HF in the right context, but values vary with age, renal function, obesity (lowers BNP), AFib, pulmonary hypertension, and acute coronary syndromes
- Troponin elevated in myocardial infarction or strain
- Lactate elevated (≥ 2 mmol/L) signals tissue hypoperfusion; ≥ 4 suggests shock
- ABG: metabolic acidosis from poor tissue perfusion (lactic acidosis)
- Cardiac index < 2.2 L/min/m² on invasive monitoring
Sample nursing diagnoses
Use this format on your care plan:
Decreased cardiac output related to [specific cause] as evidenced by [subjective + objective findings].
Five worked examples covering the most common student-assigned scenarios:
- Heart failure (HFrEF): Decreased cardiac output related to impaired left ventricular contractility (HFrEF, LVEF 30%) as evidenced by S3 gallop, bibasilar crackles, BNP 1,200 pg/mL, 2+ pitting edema bilaterally, fatigue with cool extremities and narrow pulse pressure, and self-report of dyspnea on exertion and orthopnea.
- AFib with RVR: Decreased cardiac output related to atrial fibrillation with rapid ventricular response as evidenced by HR 145 (irregular), BP 88/56, pulse deficit, lightheadedness, and reduced exercise tolerance.
- Acute MI: Decreased cardiac output related to myocardial ischemia with regional wall-motion abnormality as evidenced by substernal chest pain rated 8/10, ST-segment elevation in inferior leads on ECG, troponin elevation, diaphoresis, and cool clammy skin.
- Hypertensive heart disease: Decreased cardiac output related to increased afterload from poorly controlled hypertension as evidenced by BP 198/108, S4 gallop, fatigue with mild exertion, and dyspnea on exertion.
- Post-cardiac surgery: Decreased cardiac output related to post-bypass myocardial stunning following CABG as evidenced by cardiac index 1.8 L/min/m², MAP 58 mmHg, urine output 15 mL/hr, and need for inotropic support.
Risk for decreased cardiac output (when no actual problem yet)
For a risk diagnosis there’s no actual problem yet, so the format drops “as evidenced by” defining characteristics and uses “related to” with the patient’s risk factors only. If the patient already has hypotension, abnormal hemodynamics, or signs of hypoperfusion, that supports the actual diagnosis — not the risk diagnosis.
Risk for decreased cardiac output related to scheduled cardiac catheterization, history of severe coronary artery disease, and recent initiation of beta-blocker therapy.
Note: NANDA-I terminology for risk variants is updated periodically — verify the exact label your program requires.
Goals and outcomes (SMART format)
Strong nursing goals are Specific, Measurable, Attainable, Realistic, and Time-bound. Use a measurable hemodynamic target and a timeframe.
Short-term goals (within 1–2 hours or end of shift)
- Patient will demonstrate hemodynamic stability — HR 60–100 bpm, MAP ≥ 65 mmHg, SpO₂ within the prescribed target range — by end of shift. (Common acute-care targets vary by condition and protocol; patients at risk of hypercapnic respiratory failure such as some COPD patients may have lower targets ordered.)
- Patient will report decreased dyspnea and chest pain ≤ 3/10 within 30 minutes of intervention.
- Patient will maintain urine output ≥ 30 mL/hr (or 0.5 mL/kg/hr) by end of shift.
- Patient will exhibit alert and oriented mental status with no new confusion by end of shift.
Long-term goals (within 24–72 hours or by discharge)
- Patient will verbalize understanding of prescribed cardiac medications, including indications, doses, and red-flag side effects, prior to discharge.
- Patient will demonstrate ability to monitor daily weights and recognize fluid-retention warning signs (gain > 2 lb in 24 hours or > 5 lb in a week) prior to discharge.
- Patient will tolerate prescribed activity progression appropriate to clinical status (per cardiac rehab plan when applicable) prior to discharge.
Function-based goals
Pair every intensity goal with a function goal:
- Patient will tolerate ambulation 50 feet without significant dyspnea or chest discomfort.
- Patient will report sleeping without orthopnea (no extra pillows needed).
- Patient will participate in ADLs without rest-breaks for dyspnea.
High-yield flag: the NCLEX-RN favors patient-centered, measurable goals. If a goal can’t be evaluated as “met” or “not met,” rewrite it. For decreased cardiac output specifically, the most defensible goals use hemodynamic numbers (HR, MAP, SpO₂, urine output) rather than vague concepts like “improved cardiac function.”
Nursing assessment with rationales
Assessment items with rationales
| Assess | Why we do it | What to document |
|---|---|---|
| Vital signs (HR, rhythm regularity, BP, MAP, SpO₂, RR, temperature) | Establishes baseline and tracks trend; deterioration usually appears here first | Specific values, regularity, trend over time |
| Continuous cardiac rhythm (telemetry) | Detects arrhythmias before hemodynamic compromise | Rhythm name, rate, ectopy, response to interventions |
| Heart sounds (S1, S2, S3, S4, murmurs) | S3 = volume overload (HFrEF); S4 = stiff ventricle; new murmur = valve problem | Sound, location, intensity, change from baseline |
| Lung sounds (all lobes) | Crackles = pulmonary congestion; wheezing = “cardiac asthma” | Specific lobe, character, pre- and post-intervention |
| Peripheral pulses (radial, dorsalis pedis, posterior tibial) | Diminished or absent = decreased perfusion | Pulse character (e.g., 2+ regular vs 1+ thready) |
| Capillary refill | > 3 seconds = poor peripheral perfusion | Seconds, location |
| Skin color, temperature, moisture | Cool/clammy/cyanotic = decreased perfusion or shock | Description, change from baseline |
| JVP (head of bed at 30–45°; measured vertically) | > 3–4 cm above sternal angle = elevated right-sided pressures (RV failure, volume overload) | Centimeters above sternal angle, head-of-bed position |
| Edema (location, depth, distribution) | Quantifies fluid overload; sacral edema is often missed in bedbound patients | 1+ to 4+ scale, location |
| Mental status (LOC, orientation, agitation, new confusion) | Early sign of cerebral hypoperfusion — before BP drops | Specific changes from baseline |
| Urine output | < 30 mL/hr (or < 0.5 mL/kg/hr) signals renal hypoperfusion | Hourly volume, trend |
| Daily weights — same time, same scale, similar clothing | Most sensitive fluid-status measure; > 1–2 kg/day = fluid retention | Weight in kg, comparison to baseline |
| Chest pain (PQRSTU details) | Differentiates ischemic from non-ischemic causes | Quality, location, radiation, duration, triggers, response to nitro |
| Activity tolerance | Quantifies functional capacity; sets goal baseline | Specific task tolerated and triggering symptom |
Hemodynamic monitoring (when applicable)
| Parameter | Normal | Abnormal interpretation |
|---|---|---|
| Cardiac index | 2.5–4.0 L/min/m² | < 2.2 = decreased cardiac output |
| SVR (systemic vascular resistance) | 800–1,200 dynes·s/cm⁵ | High = vasoconstriction (heart failure); low = sepsis or distributive shock |
| PAOP (pulmonary artery occlusion pressure) | 8–12 mmHg | > 18 = left-sided failure or volume overload |
| CVP | 2–6 mmHg | > 12 = right-sided failure or volume overload |
| MAP | ≥ 65 mmHg | < 65 = inadequate organ perfusion |
Diagnostic tests
| Test | What it shows |
|---|---|
| ECG (12-lead) | Ventricular or atrial hypertrophy, axis deviation, ischemia (ST-segment changes), dysrhythmias (AFib, AV blocks, VT, frequent PVCs), bundle branch block |
| Chest X-ray | Cardiomegaly may be suggested by cardiothoracic ratio > 0.5 on an upright PA chest X-ray (portable AP films can exaggerate heart size); pulmonary vascular congestion, pleural effusion, pulmonary edema (Kerley B lines, bat-wing pattern) |
| Echocardiogram | Assesses LVEF, wall-motion abnormalities, valve function, and chamber size. HFrEF is generally LVEF ≤ 40%, HFmrEF 41–49%, and HFpEF ≥ 50%; HFpEF diagnosis also requires clinical HF plus evidence of increased filling pressures or structural/functional cardiac abnormality⁴ |
| Cardiac catheterization | Coronary anatomy and stenoses, chamber pressures, ejection fraction; differentiates ischemic from non-ischemic causes |
| Stress testing (exercise or pharmacologic) | Identifies inducible ischemia and wall-motion changes |
| BNP / NT-proBNP | Elevated in heart failure; helps differentiate cardiac from non-cardiac dyspnea |
| Troponin (high-sensitivity) | Elevated in myocardial infarction or strain |
| Electrolytes | Often abnormal from diuretics; potassium and magnesium critical for arrhythmia prevention |
| BUN / creatinine | Elevated BUN with normal creatinine suggests decreased renal perfusion; both elevated suggests renal dysfunction or acute kidney injury — interpret with urine output, eGFR, volume status, and baseline renal function |
| Lactate | ≥ 2 mmol/L signals tissue hypoperfusion; ≥ 4 suggests shock |
| ABG | Metabolic acidosis from lactic acid in poor perfusion; respiratory acidosis if patient is tiring |
| Thyroid panel | Hyperthyroidism can precipitate AFib and HF; hypothyroidism can mimic HF |
| Pulse oximetry | Continuous monitoring of oxygenation |
Nursing interventions for decreased cardiac output (with rationales)
Monitoring and assessment
| Intervention | Rationale |
|---|---|
| Continuous cardiac monitoring (telemetry) | Detects arrhythmias before hemodynamic compromise |
| Vital signs q15min–q1h initially, q4h once stable | Tracks hemodynamic trend |
| Auscultate heart and lung sounds q4–8h | Detects new S3/S4, murmurs, or worsening crackles |
| Strict intake and output, daily weights | Identifies fluid retention or response to diuretics |
| Mental-status checks each shift | Early hypoperfusion presents as confusion before BP drops |
| Monitor labs (electrolytes, BUN/Cr, BNP, troponin, lactate) | Drives medication titration; detects decompensation |
Reduce cardiac workload
| Intervention | Rationale |
|---|---|
| Position with head of bed 30–45° (upright if dyspneic) | Reduces preload and improves pulmonary gas exchange |
| Cluster nursing care to allow rest periods | Reduces sympathetic activation and oxygen demand |
| Maintain calm, quiet environment | Reduces sympathetic surge that raises HR and afterload |
| Bedside commode if ordered | Reduces Valsalva straining, which can trigger vagal events |
| Assist with ADLs during acute phase | Conserves myocardial energy |
| Stop or hold activity if symptoms worsen | Prevents decompensation |
Pharmacologic support (per orders)
| Intervention | Rationale | Watch for |
|---|---|---|
| Diuretics — furosemide, bumetanide, torsemide | Reduces preload and pulmonary congestion in fluid overload | Hypokalemia, hypomagnesemia, hypotension, ototoxicity (rapid IV push) |
| ACE inhibitors / ARBs — lisinopril, losartan, valsartan; or ARNI (sacubitril-valsartan) | Reduces afterload; mortality benefit in HFrEF per 2022 AHA/ACC/HFSA Guideline⁴ | Cough (ACEi), hyperkalemia, angioedema, hypotension, AKI. For ARNI (sacubitril-valsartan): do NOT administer concomitantly with an ACE inhibitor or within 36 hours of the last ACE-inhibitor dose; avoid in patients with a history of angioedema. |
| Beta-blockers — carvedilol, metoprolol succinate, bisoprolol | Reduces sympathetic drive; mortality benefit in HFrEF; start low and titrate up⁴ | Bradycardia, hypotension, bronchospasm (less with cardioselective agents) |
| Aldosterone antagonists — spironolactone, eplerenone | Mortality benefit in HFrEF NYHA II–IV⁴ | Hyperkalemia, AKI, gynecomastia (spironolactone) |
| SGLT2 inhibitors — dapagliflozin, empagliflozin | Newer pillar of HFrEF and HFpEF therapy per 2022 AHA/ACC/HFSA Guideline⁴ | Genital infections, euglycemic DKA, volume depletion |
| Digoxin (select patients) | Modest positive inotrope and AV-nodal slowing agent — used for select HFrEF patients and for rate control in AFib with HF | Narrow therapeutic window — toxicity → arrhythmias, GI symptoms, visual changes (yellow halos) |
| Inotropes — dobutamine, milrinone (acute decompensation) | Increases contractility short-term in cardiogenic shock | Arrhythmias, hypotension (milrinone); not for chronic outpatient use |
| Antiarrhythmics — amiodarone, others | Restores or maintains rhythm to improve CO | Long QT, pulmonary toxicity (amiodarone), bradycardia |
| Anticoagulation in AFib — warfarin or DOAC, per CHA₂DS₂-VASc score | Reduces stroke risk in AFib | Bleeding, drug interactions, INR monitoring for warfarin |
| Vasopressors — norepinephrine (first-line), epinephrine, vasopressin (per shock guidelines) | Maintains MAP ≥ 65 mmHg in cardiogenic or distributive shock | Tissue ischemia at extravasation; arrhythmias |
| Vasodilators / antihypertensives | Reduces afterload in hypertensive heart failure | Hypotension, reflex tachycardia |
Oxygen and ventilation
| Intervention | Rationale |
|---|---|
| Titrate supplemental oxygen to the prescribed target; avoid routine oxygen in normoxemic ACS; for patients at risk of hypercapnic respiratory failure (e.g., some COPD patients), lower targets may be ordered | Corrects hypoxemia without overshooting; routine oxygen in non-hypoxic patients is not currently recommended⁵ |
| Consider noninvasive ventilation (BiPAP, CPAP) per orders for acute pulmonary edema | Reduces work of breathing and preload; can avoid intubation |
| Prepare for intubation if respiratory failure imminent | Worsening hypercapnia, exhaustion, falling LOC = late signs |
Fluid and electrolyte management
| Intervention | Rationale |
|---|---|
| Fluid restriction per orders (often 1.5–2 L/day in advanced HF) | Reduces preload and pulmonary congestion |
| Sodium restriction per orders (often 2–3 g/day in HF) | Reduces fluid retention |
| Monitor electrolytes daily (K+, Mg++, Na+, BUN/Cr) | Diuretics and RAAS blockers disturb electrolytes; K+ and Mg++ replacement prevents arrhythmias |
| Replace potassium and magnesium per protocol | Hypokalemia and hypomagnesemia precipitate arrhythmias |
Patient education and lifestyle
| Intervention | Rationale |
|---|---|
| Daily weight education (same time, scale, clothing) | Earliest sign of fluid retention — weight gain > 2 lb/24 h or > 5 lb/week should trigger a call to the provider |
| Sodium-restricted diet teaching | Reduces fluid retention |
| Smoking cessation counseling | Reduces afterload and myocardial oxygen demand; refer to CDC tobacco cessation resources⁸ |
| Medication adherence and side-effect education | Medication nonadherence, medication complexity, diet/fluid issues, inadequate follow-up, and worsening comorbidities are common contributors to HF readmissions |
| Cardiac rehab referral when eligible | Improves functional capacity, exercise tolerance, quality of life, and supports secondary prevention after ACS / HF hospitalization⁴,⁵ |
| Recognize HF red flags (worsening SOB, weight gain, increasing edema, fatigue, chest pain) | Early reporting prevents readmission |
Monitor for
- Worsening hemodynamics — falling MAP, rising lactate, increasing vasopressor requirements
- Worsening dyspnea, new or expanding pulmonary congestion
- New or worsening arrhythmia
- Digoxin toxicity in patients on digoxin (GI symptoms, visual changes, arrhythmias)
- Electrolyte abnormalities from diuretics (K+, Mg++)
- Bleeding in anticoagulated patients
- Renal function decline (rising BUN/Cr)
- Impending cardiogenic shock — cool extremities, mottling, oliguria, altered LOC, rising lactate
Sample care plans (5 scenarios)
Scenario 1 — Heart Failure (HFrEF)
Diagnostic statement: Decreased cardiac output related to impaired left ventricular contractility (HFrEF, EF 30%) as evidenced by S3 gallop, bibasilar crackles, BNP 1,200 pg/mL, 2+ pitting edema bilaterally, and self-report of orthopnea requiring 3 pillows.
Short-term goal: Patient will demonstrate decreased pulmonary congestion (clearing crackles, decreased dyspnea, negative fluid balance and weight trend toward ordered goal) within 24 hours of diuresis.
Assessment: Daily weights at same time and scale; strict I&O; lung auscultation q4h; SpO₂ continuous; electrolyte panel daily; BNP trend; vital signs q4h; mental status; activity tolerance.
Interventions: Administer IV diuretic (furosemide) per orders and monitor response; administer guideline-directed medical therapy as prescribed (ACEi/ARB/ARNI, beta-blocker, aldosterone antagonist, SGLT2 inhibitor) per 2022 AHA/ACC/HFSA Guideline⁴ — monitor blood pressure, heart rate, renal function, potassium, volume status, adverse effects, and tolerance; communicate findings that may require provider adjustment; sodium restriction (typically 2–3 g/day) and fluid restriction (1.5–2 L/day) per orders; elevate head of bed to 30–45°; cluster care for rest periods; teach daily weights and red-flag symptoms; cardiac rehab referral.
Evaluation: Weight trending down, breath sounds clearing, BNP trending down, dyspnea decreased, patient verbalizes understanding of medication and self-monitoring plan.
Scenario 2 — Acute Myocardial Infarction
Diagnostic statement: Decreased cardiac output related to myocardial ischemia with regional wall-motion abnormality as evidenced by substernal chest pain rated 8/10, ST-segment elevation in inferior leads, troponin elevation, and diaphoresis.
Short-term goal: Patient will report chest pain ≤ 2/10 within 30 minutes of intervention and maintain MAP ≥ 65 mmHg and SpO₂ within the prescribed target range — administer oxygen only if hypoxemic (SpO₂ < 90%), in respiratory distress, or otherwise ordered per protocol.
Assessment: Continuous cardiac monitoring; serial 12-lead ECGs; troponin trend; vital signs q5–15 min during active pain; bleeding precautions for anticoagulation.
Interventions: For suspected ACS, prioritize rapid ECG and troponins, continuous cardiac monitoring, IV access, aspirin if not contraindicated, nitroglycerin as ordered if BP and right-ventricular-infarct / PDE-5-inhibitor precautions allow, oxygen only for hypoxemia or respiratory distress (SpO₂ < 90%) — routine oxygen is no longer recommended in non-hypoxic ACS, and opioid analgesia (morphine or fentanyl) only for persistent severe ischemic pain despite anti-ischemic therapy. Prepare for urgent reperfusion or cath-lab activation when indicated per 2025 ACC/AHA ACS Guideline.⁵
Evaluation: Pain controlled, hemodynamics stable, ischemia not progressing, troponin peaking and trending down.
See: Myocardial Infarction Nursing Care Plan · Chest Pain Nursing Care Plan
Scenario 3 — Atrial Fibrillation with RVR
Diagnostic statement: Decreased cardiac output related to atrial fibrillation with rapid ventricular response as evidenced by HR 145 (irregularly irregular), BP 88/56, pulse deficit (apical–radial mismatch of 12 beats), lightheadedness, and reduced exercise tolerance.
Short-term goal: Patient will achieve rate control (HR < 110) and BP > 100 systolic within 1 hour of intervention.
Assessment: Continuous cardiac monitoring with rhythm strip documentation; vital signs q15 min during active treatment; apical–radial pulse check for pulse deficit; mental status; signs of hemodynamic compromise (cool extremities, mottling, falling urine output); CHA₂DS₂-VASc score for stroke risk; HAS-BLED for bleeding risk.
Interventions: Because this patient has AFib with RVR plus hypotension and symptoms of decreased perfusion, treat as hemodynamically unstable: notify provider / rapid-response team, maintain airway and oxygenation if hypoxemic, continue cardiac monitoring, obtain IV access, prepare for synchronized cardioversion per ACLS / provider order, and anticipate sedation if feasible. If the patient is stable, rate-control medications may be used per orders, with agent selection based on blood pressure, ejection fraction, heart failure status, and contraindications. Medication safety: avoid or use extreme caution with IV diltiazem or verapamil in patients with HFrEF, decompensated heart failure, shock, or significant hypotension — non-dihydropyridine calcium-channel blockers with negative inotropic effects may be harmful in patients with LVEF ≤ 40%. Initiate anticoagulation per CHA₂DS₂-VASc score; address reversible triggers (electrolyte abnormalities, thyroid, alcohol, infection, hypoxia, ischemia); teach patient about AFib, rate vs rhythm control, stroke risk, and anticoagulation safety.
Evaluation: Rate controlled, hemodynamics improving, patient hemodynamically stable, anticoagulation plan in place.
Scenario 4 — Cardiogenic Shock
Diagnostic statement: Decreased cardiac output related to severe left ventricular dysfunction following anterior STEMI as evidenced by MAP 52 mmHg despite norepinephrine, cardiac index 1.6 L/min/m², lactate 5.2 mmol/L, urine output 10 mL/hr, cold mottled extremities, and decreased level of consciousness.
Short-term goal: Patient will maintain MAP ≥ 65 mmHg, cardiac index ≥ 2.2 L/min/m², and decreasing lactate trend within 4 hours.
Assessment: Continuous hemodynamic monitoring (arterial line, central line, possibly PA catheter or non-invasive CO monitoring); cardiac rhythm; serial lactate q2–4h; urine output hourly; mental-status checks; skin perfusion; mechanical ventilation parameters if intubated.
Interventions: Titrate vasopressors and inotropes per orders (typically norepinephrine for vasoconstriction + dobutamine or milrinone for inotropy); prepare for mechanical circulatory support per cardiology team (intra-aortic balloon pump, Impella, ECMO) if pharmacologic support inadequate; coordinate emergent reperfusion (cath lab) for STEMI cause; correct underlying cause (revascularization, valve repair, tamponade drainage); ensure adequate oxygenation (often mechanical ventilation); manage acidosis; monitor and treat arrhythmias; family communication and goals-of-care discussion when appropriate.
Evaluation: Hemodynamics improving on support, lactate clearing, urine output returning, mental status improving — or escalate to mechanical support and ICU-level intervention if not.
Scenario 5 — Post-Cardiac Surgery (CABG)
Diagnostic statement: Decreased cardiac output related to post-bypass myocardial stunning following 3-vessel CABG as evidenced by cardiac index 1.9 L/min/m², MAP 60 mmHg requiring vasopressor and inotrope, urine output 20 mL/hr, and need for ongoing hemodynamic support 6 hours post-op.
Short-term goal: Patient will demonstrate hemodynamic stabilization with cardiac index ≥ 2.2, MAP ≥ 65, and decreasing vasopressor requirement within 12 hours.
Assessment: Continuous hemodynamic monitoring; chest tube output (concerning if > 200 mL/hr or sudden cessation with tamponade signs); rhythm monitoring (post-op AFib is common); sternal precautions; pain control; respiratory status; bleeding precautions; signs of tamponade (Beck’s triad — hypotension, JVD, muffled heart sounds — though heart sounds often muffled post-op anyway).
Interventions: Titrate inotropes (typically dobutamine, milrinone, or epinephrine) and vasopressors per orders; manage volume status (myocardial stunning often improves with cautious volume + inotropy); aggressive pain management to reduce sympathetic load; early extubation when criteria met; sternal precautions teaching when extubated; monitor and treat post-op AFib (common after cardiac surgery; often resolves with electrolyte correction and amiodarone per orders); progressive cardiac rehab beginning early.
Evaluation: Hemodynamics improving, vasopressor/inotrope weaning, extubation achieved on schedule, no significant bleeding or tamponade signs, patient progressing through expected post-op recovery.
Escalation red flags (high-yield)
| Situation | Escalate for |
|---|---|
| Any patient | Rapidly worsening hemodynamics, MAP < 65 despite intervention, new altered LOC, rising lactate, falling urine output |
| Heart failure | Rapid weight gain > 2 lb/24 h, pink frothy sputum, single-word dyspnea, hypoxia not responding, signs of cardiogenic shock |
| ACS / MI | Ongoing chest pain despite anti-ischemic therapy, hypotension, new heart sounds, new dysrhythmia, ST-segment evolution |
| AFib with RVR | HR sustained > 150 despite rate control, hypotension, altered mental status, syncope, signs of decompensation |
| Cardiogenic shock | Rising lactate despite vasopressors, cold mottled extremities, oliguria, falling MAP — escalate to mechanical circulatory support team |
| Post-cardiac surgery | Chest tube > 200 mL/hr or sudden cessation, Beck’s triad (tamponade), new bleeding, hemodynamic deterioration |
Discharge and patient teaching
| Teaching point | What the nurse explains |
|---|---|
| Daily weights | Same time, same scale, similar clothing; call provider for gain > 2 lb in 24 hours or > 5 lb in a week |
| Sodium-restricted diet | Read labels; aim for prescribed limit (commonly 2–3 g/day in HF) |
| Fluid restriction (if prescribed) | Track intake; usually 1.5–2 L/day in advanced HF |
| Medication adherence | Especially diuretics, ACEi/ARB/ARNI, beta-blockers, SGLT2 inhibitors — do not skip; many HF readmissions are medication-related |
| Recognize HF symptoms | Increasing SOB, orthopnea, PND, fatigue, edema, decreased exercise tolerance |
| When to call 911 | Chest pain not relieved by rest or nitro, severe SOB, syncope, signs of stroke |
| Cardiac rehab | Improves functional capacity, exercise tolerance, and quality of life; supports secondary prevention after ACS / HF hospitalization⁴,⁵ |
| Vaccinations | Annual influenza and pneumococcal vaccines per current CDC/ACIP schedule⁸ |
| Smoking cessation and alcohol moderation | Reduces afterload and oxygen demand; smoking impairs healing |
| Anticoagulation safety (if on warfarin/DOAC) | Bleeding precautions, drug interactions, dietary considerations (warfarin: consistent vitamin K intake) |
| Pacemaker / ICD precautions (if applicable) | Avoid strong magnets, follow device-team instructions |
Frequently asked questions
What is decreased cardiac output?
Decreased cardiac output is a NANDA-I nursing diagnosis describing inadequate blood pumped by the heart to meet the body’s metabolic demands.¹ It can result from altered heart rate or rhythm, altered contractility, altered preload, or altered afterload.
What does decreased cardiac output mean on a care plan?
It means the heart isn’t pumping enough blood to meet the body’s needs, putting the patient at risk for hypoxemia, organ hypoperfusion, fluid backup, and shock. The care plan focuses on maintaining hemodynamic stability, reducing cardiac workload, supporting the underlying condition, and educating the patient.
What are the risk factors for decreased cardiac output?
Heart failure, myocardial infarction, dysrhythmias (especially AFib with RVR, VT, complete heart block), cardiomyopathy, valvular disease, severe hypertension, fluid overload, hypovolemia, cardiogenic shock, recent cardiac surgery, sepsis, and negative-inotropic medications.
What’s the difference between decreased cardiac output and ineffective tissue perfusion?
Decreased cardiac output is about the pump — the heart can’t move enough blood. Ineffective tissue perfusion is downstream — even if cardiac output is adequate, blood may not be reaching specific tissues (peripheral, cerebral, renal, cardiopulmonary, GI). A patient with decreased cardiac output almost always has ineffective tissue perfusion as a secondary diagnosis.
How do you write a SMART goal for decreased cardiac output?
Use a measurable hemodynamic target and a timeframe. Instead of “Patient will have better cardiac function,” write “Patient will maintain MAP ≥ 65 mmHg, HR 60–100 bpm, and SpO₂ within the prescribed range by end of shift.” Pair every intensity goal with a function goal — tolerate ambulation 50 feet, sleep without orthopnea, complete ADLs without symptoms.
What does “as evidenced by” mean for decreased cardiac output?
The “as evidenced by” portion of the diagnostic statement lists the specific findings that prove the diagnosis applies to this patient — typically vital sign abnormalities, S3 gallop, JVD, crackles, peripheral edema, decreased urine output, altered mental status, and laboratory findings (BNP, troponin, lactate, cardiac index).
Practice questions
Based on the client case (HF presentation), what are the symptoms predictive of heart failure?
Answer: Shortness of breath, fatigue, edema, weight gain, orthopnea, decreased exercise tolerance.
Changes in what lab value are most suggestive of renal failure in clients with decreased cardiac output?
- AST
- BUN and creatinine (both)
- Troponin
- HDL
Answer: 2. Elevated BUN alone can reflect decreased renal perfusion; elevation of both BUN and creatinine signals established renal failure.
Which medication class should be used with extreme caution in patients with HFrEF?
- ACE inhibitors
- Beta-blockers (cardioselective)
- Non-dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem) — avoid in HFrEF due to negative inotropic effects
- SGLT2 inhibitors
Answer: 3. Per 2022 AHA/ACC/HFSA guidance, non-dihydropyridine CCBs (verapamil, diltiazem) are avoided in HFrEF because of negative inotropic effects.⁴
Which exam directly measures ejection fraction and wall motion?
- Chest X-ray
- ECG
- Echocardiogram
- Stress test
Answer: 3.
The units of cardiac output are:
- L
- L/min
- m³
- mL
Answer: 2.
Related care plans
- Congestive Heart Failure (CHF) Nursing Care Plan
- Myocardial Infarction Nursing Care Plan
- Chest Pain Nursing Care Plan
- Hypertension Nursing Care Plan
- Pulmonary Embolism Nursing Care Plan
- Edema Nursing Care Plan
- Ineffective Tissue Perfusion Nursing Care Plan
- Acute Pain Nursing Care Plan
Decreased cardiac output care plans look intimidating until you realize they follow a clear skeleton — NANDA statement, hemodynamic assessment, intervention, evaluation. Lock the skeleton in once and every scenario (HF, MI, AFib, shock, post-op) becomes a fill-in-the-blank. You’ve got this.
Ready to test what you just learned? Try a few cardiovascular and hemodynamics practice questions in NCLEX format and lock in the priority-action patterns before test day.
Nursing Care Plan Resources
References
- Herdman TH, Kamitsuru S, Lopes CT, eds. NANDA International Nursing Diagnoses: Definitions and Classification, 2024–2026. 13th ed. Thieme; 2024. Publisher product page
- King J, Lowery DR. Physiology, Cardiac Output. In: StatPearls. Treasure Island (FL): StatPearls Publishing; current update. NCBI Bookshelf NBK470455
- Vincent JL. Understanding cardiac output. Crit Care. 2008;12(4):174. PMC2575587
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263–e421. AHA/ACC/HFSA 2022 Heart Failure Guideline
- Writing Committee, American College of Cardiology / American Heart Association / American College of Emergency Physicians / National Association of EMS Physicians / Society for Cardiovascular Angiography and Interventions. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. acc.org guideline hub
- American Heart Association. Advanced Cardiovascular Life Support (ACLS) — current edition. cpr.heart.org
- Ernstmeyer K, Christman E, eds. Nursing Fundamentals. Chippewa Valley Technical College; 2021. NCBI Bookshelf
- Centers for Disease Control and Prevention (CDC). Heart Disease Facts and Statistics; Tobacco cessation resources; current CDC/ACIP immunization schedule. cdc.gov/heart-disease · cdc.gov/tobacco · cdc.gov/vaccines/schedules
